Advertisement

Topics

How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?

19:57 EDT 18 Oct 2016 | SCRIP

Following Sandoz’s Zarxio playbook, Pfizer plans to market Inflectra while patent litigation continues; February 2017 trial on cell culture media...

      

Related Stories

 

Original Article: How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?

NEXT ARTICLE

More From BioPortfolio on "How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?"

Quick Search
Advertisement
 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Cell Culture
Types of Cell Culture Open https://www.youtube.com/watch?v=WGKoJRNKADY to view video on cell culture basics. Four catagories of cell culture techniques are listed below: Adherent cells Cells shown to require attachment for growth are sa...